Diéras V - Search Results

1

Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Le Tourneau C, Diéras V, Tresca P, Cacheux W, Paoletti X. Le Tourneau C, et al. Among authors: dieras v. Target Oncol. 2010 Mar;5(1):65-72. doi: 10.1007/s11523-010-0137-6. Epub 2010 Apr 2. Target Oncol. 2010. PMID: 20361265 Review.

2

Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.

Dittrich C, Dieras V, Kerbrat P, Punt C, Sorio R, Caponigro F, Paoletti X, de Balincourt C, Lacombe D, Fumoleau P. Dittrich C, et al. Among authors: dieras v. Invest New Drugs. 2003 Aug;21(3):347-52. doi: 10.1023/a:1025476813365. Invest New Drugs. 2003. PMID: 14578683 Clinical Trial.

3

[Targeting epidermal growth factor receptor in cancer of the breast].

Diéras V, Pierga JY, Vincent-Salomon A, Beuzeboc P, Pouillart P, de Cremoux P. Diéras V, et al. Bull Cancer. 2003 Nov;90 Spec No:S257-62. Bull Cancer. 2003. PMID: 14763149 Free article. French.

4

[Update on docetaxel and breast cancer].

Diéras V, Girre V, Pierga JY, Laurence V, Piperno-Neumann S, Pouillart P. Diéras V, et al. Bull Cancer. 2004 May;91(5):409-17. Bull Cancer. 2004. PMID: 15281280 Free article. Review. French.

5

[Oxaliplatin and ovarian cancer].

Dieras V, Girre V, Guilhaume MN, Laurence V, Mignot L. Dieras V, et al. Bull Cancer. 2006 Feb 1;93 Suppl 1:S35-9. Bull Cancer. 2006. PMID: 16483943 Review. French.

6

[Phase I cancer trials methodology].

Le Tourneau C, Faivre S, Raymond E, Diéras V. Le Tourneau C, et al. Among authors: dieras v. Bull Cancer. 2007 Nov;94(11):943-51. Bull Cancer. 2007. PMID: 18055311 Free article. French.

7

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.

Le Tourneau C, Faivre S, Laurence V, Delbaldo C, Vera K, Girre V, Chiao J, Armour S, Frame S, Green SR, Gianella-Borradori A, Diéras V, Raymond E. Le Tourneau C, et al. Among authors: dieras v. Eur J Cancer. 2010 Dec;46(18):3243-50. doi: 10.1016/j.ejca.2010.08.001. Epub 2010 Sep 6. Eur J Cancer. 2010. PMID: 20822897 Clinical Trial.

8

Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.

Le Tourneau C, Dettwiler S, Beuzeboc P, Alran S, Laurence V, Pierga JY, Fréneaux P, Sigal-Zafrani B, Diéras V, Vincent-Salomon A. Le Tourneau C, et al. Among authors: dieras v. Am J Clin Oncol. 2012 Jun;35(3):242-6. doi: 10.1097/COC.0b013e318209d34c. Am J Clin Oncol. 2012. PMID: 21358298

9

Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature.

Le Tourneau C, Razak AR, Gan HK, Pop S, Diéras V, Tresca P, Paoletti X. Le Tourneau C, et al. Among authors: dieras v. Eur J Cancer. 2011 Jul;47(10):1468-75. doi: 10.1016/j.ejca.2011.03.016. Epub 2011 Apr 7. Eur J Cancer. 2011. PMID: 21482105 Review.

10

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

Leijen S, Middleton MR, Tresca P, Kraeber-Bodéré F, Dieras V, Scheulen ME, Gupta A, Lopez-Valverde V, Xu ZX, Rueger R, Tessier JJ, Shochat E, Blotner S, Naegelen VM, Schellens JH, Eberhardt WE. Leijen S, et al. Among authors: dieras v. Clin Cancer Res. 2012 Sep 1;18(17):4794-805. doi: 10.1158/1078-0432.CCR-12-0868. Epub 2012 Jul 5. Clin Cancer Res. 2012. PMID: 22767668 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

288 results

Search Page